Literature DB >> 8811069

Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies.

S J Seligman1, J M Binley, M K Gorny, D R Burton, S Zolla-Pazner, K A Sokolowski.   

Abstract

Characterization of the sites recognized by antibody on the V3 loop of the envelope glycoprotein gp120 of HIV-1 was done by competition ELISAs on a series of four mouse mAbs, a human mAb and a human Fab. The solid-phase antigen consisted of biotin-YNKRK-RIHIGPGRAFYTTKN, a sequence from the center of the V3 loop of gp120MN, applied to streptavidin-coated wells. Competing antigens were two series of peptides with the HIV-1MN sequence each serially deleted at either the N or C terminus but kept constant at the other terminus. For each series, the amino acid at the deleting end needed to give a minimum KD was identified. The epitope was defined as the sequence including both of the identified amino acids as terminal amino acids. For the six antibodies reported, the epitope length ranged from seven to 14 amino acids. Use of a cyclic peptide as competing fluid-phase antigen suggested the influence of conformational constraints on presumed "linear" epitopes. The operationally-defined epitope was longer than the contact residues in one of two instances in which the X-ray crystallographic structure had been determined. The longer estimates of epitope length in the current study based on competition ELISAs with serial deletions suggest that non-contact residues are significant both in epitope definition and in functional applications including immunogen design.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811069     DOI: 10.1016/0161-5890(96)00044-2

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

3.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Authors:  Cheryl J Saunders; Ruth A McCaffrey; Irina Zharkikh; Zane Kraft; Susan E Malenbaum; Brian Burke; Cecilia Cheng-Mayer; Leonidas Stamatatos
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Authors:  Ralph Pantophlet; Terri Wrin; Lisa A Cavacini; James E Robinson; Dennis R Burton
Journal:  Virology       Date:  2008-09-26       Impact factor: 3.616

8.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.

Authors:  N Sullivan; Y Sun; J Binley; J Lee; C F Barbas; P W Parren; D R Burton; J Sodroski
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.